CD163 is a marker of macrophages with anti-inflammatory properties and its soluble form (sCD163) is considered a prognostic predictor of several diseases including type 2 diabetes mellitus (T2DM).
Introduction
Obesity induces chronic low-grade inflammation connected with macrophage accumulation in adipose tissue (Weisberg et al. 2003) . These macrophages may contribute to inflammatory and metabolic complications of obesity (Olefsky and Glass 2010) . It has been shown that both the number of macrophages and their pro-inflammatory phenotype can be changed by modifications of energy intake, energy expenditure and adipose tissue mass (Aron-Wisnewsky et al. 2009 ).
Macrophages can exist in two main activation states: the classically activated pro-inflammatory (M1) and the alternatively activated anti-inflammatory (M2) macrophages regulated by proinflammatory and anti-inflammatory cytokines, respectively (Gustafsson et al. 2008) . In our study, we focused on alternatively activated macrophages with potentially anti-inflammatory marker CD163.
CD163 receptor is a member of the scavenger receptor cysteine-rich superfamily (SRCR), class B. The SRCR domain forms a common structural fold with six-stranded β sheet cradling an alpha helix. In humans, CD163 contains extracellular region of nine SRCR domains, cytoplasmic tail and one transmembrane element (Fabriek et al. 2005) . The best characterized function of CD163 is endocytosis of hemoglobin-haptoglobin complexes and its expression is connected with antiinflammatory processes (Schaer et al. 2006) . Although its biological action in inflammation is not precisely known, its soluble form sCD163 was suggested as a useful predictor of the development or prognosis of several diseases including type 2 diabetes mellitus (T2DM) (Moller et al. 2011), infection by human immunodeficiency virus (Burdo et al. 2011) or several types of cancer (Lan et al. 2013 , Wang et al. 2015 . Interestingly, despite its suggested anti-inflammatory and scavenging properties CD163 was found to be expressed mainly on the classical proinflammatory monocytes (CD14++CD16-) as compared with the non-classical subset (CD14dimCD16++) despite the latter's role in tissue patrolling and control of vascular integrity (Ziegler-Heitbrock 2007) .
Thus, we hypothesized that circulating sCD163 and its mRNA expression in adipose tissue may be connected to inflammatory state and modified by weight-reducing interventions. To this end, we explored the changes of plasma sCD163 levels, its mRNA expression and CD163 positive cells in circulating monocyte subsets and adipose tissue in subject with simple obesity and obesity complicated by T2DM relative to lean healthy control subjects and its modulation by very low-calorie diet (VLCD) and bariatric surgery.
Methods

Study subjects
Thirty two obese patients, 32 obese patients with T2DM and 19 age-matched lean healthy control subjects were included into the study. Control subjects had been free of any medication and had no history of obesity or diabetes mellitus. The inclusion criteria for study subjects were age between 40 and 60 years and BMI (Body mass index) higher than 35 kg/m 2 . Patients of both genders were included as previous studies have shown that changes of CD163 are not on gender- et al. , Fjeldborg et al. 2013 . Written informed consent was signed by each subject and the studies were approved by the Human Ethics Committee, First Faculty of Medicine and General University Hospital, Prague, Czech Republic.
Very low-calorie diet
Forty two patients -20 with obesity and 22 obese patients with T2DM underwent 3 weeks of VLCD during hospitalization at the Third Department of Medicine, General University Hospital, Prague, Czech Republic. The energy content of VLCD was 2500 kJ per day. Anthropometry, blood and subcutaneous adipose tissue (SAT) samples were taken before and after VLCD.
Bariatric surgery
Twenty two patients -12 patients with obesity and 10 obese patients with T2DM underwent selected bariatric surgical procedures. The operations included gastric plication (12 patients), sleeve gastrectomy (6 patients), gastric bypass (3 patients) and gastric banding (1 patient).
Anthropometry, blood and SAT samples were taken before (visit 1) and 1 month, (visit 2), 6 months (visit 3) and 1 year after bariatric surgery (visit 4). During bariatric surgery, samples of visceral adipose tissue (VAT) and SAT were taken for the evaluation of mRNA expression differences between these depots.
Anthropometric examination, blood and adipose tissue sampling
All subject enrolled in the study underwent anthropometric examination and their BMI was calculated. Blood samples were taken after an overnight fasting and centrifuged for 10 min at 1000 x g within 30 min after withdrawal. Serum or plasma aliquots were subsequently stored at -80 °C.
Samples of SAT were obtained by needle aspiration biopsy from abdominal region after an overnight fasting and subsequently stored at -80 °C, as were samples of SAT and VAT obtained during bariatric surgery.
Hormonal and biochemical assays
Plasma sCD163 levels were measured by sandwich enzyme immunoassay using a commercial ELISA kit (Aviscera bioscience, Inc., Santa Clara, USA). The whole assay including plasma dilution was done according to the manufacturer's protocol. Sensitivity was 50.0 pg/ml. Serum leptin levels were measured by a commercial ELISA kit (Biovendor, Brno, Czech Republic).
Sensitivity was 0.2 ng/ml. Serum C-reactive protein (CRP) levels were measured by high sensitive ELISA kit (Bender Medsystems, Vienna, Austria) with a sensitivity of 3 pg/ml. Insulin levels were measured by RIA kit (Cis Bio International, Gif-sur-Yvette, France). Sensitivity was 2.0 µIU/ml. The intra-and interassay variabilities for all assays were between 5.0 and 10.0 %. 
Statistical analysis
Statistical analysis was performed on SigmaStat 3.0 and graphs were drawn using Signed-Rank were used for the assessment of intergroup differences, as appropriate. Spearman or
Pearson correlation test was used to assess the association between CD163 and other parameters.
The combined group of patients with healthy control subjects was used for correlation analyses.
Multiple linear regression analysis using backward stepwise variable selection method was performed in combined group using parameters with significant result from Spearman or Pearson correlation test. Statistical significance was assigned to p<0.05.
Results
Baseline characteristics of the study subjects
Obese patients had higher BMI, insulin, leptin and CRP levels and HOMA index and reduced HDL cholesterol levels compared with control subjects (Table 1) . Plasma sCD163 levels were increased relative to control subjects (Fig. 1a ).
Obese patients with T2DM had higher BMI, blood glucose, glycated hemoglobin, triglycerides, insulin, leptin and CRP levels and HOMA index and decreased HDL cholesterol compared with control subjects (Table 1) . Plasma sCD163 levels were increased (Fig. 1a) . Obese patients with T2DM had higher blood glucose, glycated hemoglobin, triglycerides and HOMA index relative to subjects with simple obesity; however, no difference in plasma sCD163 (Fig. 1a) or its mRNA expression in either SAT or CD14+ cells (Table 1) could be seen between the diabetic and obese non-diabetic group. When comparing depot-specific differences in CD163 mRNA expression in subjects enrolled in the bariatric surgery sub-study, SAT showed lower expression levels relative to VAT (2.14 ± 0.17 vs. 3.24 ± 0.41, p=0.019).
The effect of very low-calorie diet
Three weeks of VLCD reduced BMI, blood glucose, CRP and leptin levels and HOMA index in obese subjects both with and without T2DM (Table 2) . Also, their plasma sCD163 levels were reduced after VLCD (Fig. 1b) . Additionally, in obese diabetics reduced total, HDL and LDL cholesterol were found after VLCD ( Table 2 ).
The effect of bariatric surgery
Bariatric surgery in obese patients without T2DM decreased BMI, glycated hemoglobin, leptin (Table 3 ) and plasma sCD163 levels (Fig. 1c) relative to baseline and these changes lasted throughout the study.
Bariatric surgery in obese patients with T2DM decreased BMI, glycated hemoglobin, insulin and leptin levels and HOMA index relative to baseline and these changes lasted throughout the study (Table 3) . HDL cholesterol decreased transiently 1 month after surgery. Plasma sCD163 levels tended to decrease after bariatric surgery but the difference did not reach statistical significance (Fig. 1d) .
Relationship of CD163 to other studied parameters
In a combined group of obese patients with and without T2DM and control subjects CD163 mRNA expression in SAT positively correlated with serum triglycerides (R=0.266, p=0.017). Furthermore, we found a positive correlation of alanine aminotransferase levels and sCD163 (R=0.440, p=0.040) in subjects who underwent bariatric surgery. In addition, we found a strong positive correlation between CD163 mRNA expression in VAT and basal sCD163 levels (R=0.803, p=0.016).
Changes of immunocompetent cell composition in peripheral blood and subcutaneous adipose tissue
We studied the changes of immunocompetent cell composition by flow cytometry in 11 obese patients with and without T2DM from the bariatric sub-study, who underwent gastric plication.
In peripheral blood populations of classical, non-classical and intermediate monocytes based on CD14 and CD16 expression and populations of CD163+ monocytes were defined. At baseline, the patients had decreased classical monocytes (CD14++CD16-) and CD163+CD14+ cells and increased non-classical monocytes (CD14dimCD16++) compared with control subjects and these changes lasted also after gastric plication (Table 4) . (Table 4) .
Discussion
Subclinical inflammation occurring primarily in the adipose tissue plays an important role in the development of metabolic complications of obesity and ultimately in the increased risk of cardiovascular morbidity and mortality. Here we studied the changes of sCD163 (a marker of alternatively activated macrophages), peripheral blood CD163+ cells and two subpopulations of CD163+ cells in the stromal vascular fraction of subcutaneous adipose tissue in patients with obesity with or without type 2 diabetes mellitus. To explore the role of CD163 in the regulation of systemic and adipose tissue inflammatory response, we prospectively studied the changes of the above mentioned parameters after selected weight-reducing interventions that included very low-calorie diet and bariatric surgery. Furthermore, soluble sCD163 has potential anti-inflammatory effects as an inhibitor of phorbol ester-induced T lymphocytes activation and proliferation as well as matrix metalloproteinase-9 activity (Frings et al. 2002, Hogger and Sorg 2001) . It was previously described that sCD163 levels are increased in several diseases including obesity and T2DM (Moller et al. 2011 , Parkner et al. 2012 , Zanni et al. 2012 . In agreement with these data, we found increased baseline sCD163 levels in both obese patients with and without T2DM and positive correlations between sCD163 and assessed biochemical parameters such as serum triglycerides, blood glucose and glycated hemoglobin confirming its association with metabolic dysregulations present in obesity.
Moreover, multiple linear regression analysis revealed that glycated hemoglobin and C-reactive protein levels were independent predictors of sCD163 levels. As expected (Fjeldborg et al. 2013 , Kazankov et al. 2015 , both VLCD and bariatric surgery decreased sCD163 which corresponds with global metabolic improvements after both interventions. Taken together, our results suggest that sCD163 could be useful as a marker of global metabolic risk of obese subjects reflecting both the inflammatory response and the metabolic control.
In contrast to changes of circulating sCD163 levels, mRNA expression of CD163 in SAT or in CD14+ cells was not affected by obesity, diabetes or weight reducing interventions. These results are in disagreement with some previously published studies (Fjeldborg et al. 2014 , ShakeriManesch et al. 2009 ), which found increased mRNA expression of CD163 in SAT in obese subjects. In our study, only patients enrolled in the VLCD sub-study tended to have elevated mRNA expression in SAT compared with control subjects, but the difference did not reach statistical significance. We also did not find the previously described association between circulating sCD163 levels and its mRNA expression in SAT (data not shown) (Kracmerova et al.
2014
). The lack of association between circulating sCD163 and its mRNA expression in SAT in our study may suggest that sCD163 could come from other substantial sources than subcutaneous adipose tissue. For instance, enhanced production of sCD163 was previously described in obese subjects with non-alcoholic fatty liver disease (NAFLD) (Kazankov et al. 2014 , Kazankov et al. 2015 . In line with this possibility, we found a positive correlation of alanine aminotransferase levels and sCD163 indirectly supporting a possible interconnection between circulating sCD163
and NAFLD. Furthermore, another potential source of sCD163, which can respond differently to metabolic state than SAT, might be the visceral adipose tissue depot (VAT). Here, we observed a higher mRNA expression of CD163 in VAT relative to SAT as well as a positive correlation between CD163 mRNA expression in VAT and basal sCD163 levels suggesting that VAT could be in fact a more important source of circulating sCD163 than subcutaneous fat in our patients.
These data are in line with the previously described positive correlation between VAT CD163 mRNA expression or VAT to SAT depot ratio and sCD163 and with a multivariate analysis proving VAT CD163 mRNA expression as independent predictor of sCD163 in obese T2DM
males (Sorensen et al. 2015) . The difference between SAT and VAT CD163 mRNA expression might be most probably explained by increased macrophage numbers in VAT versus SAT (Harman-Boehm et al. 2007 ).
We also explored the differences in circulating monocyte subsets between obese and lean subjects based on previously described findings suggesting their modulation by obesity and its similarly to resident macrophages in the intestine (Smith et al. 1997) . In general, these cells have some features of macrophages such as phagocytosis, anti-microbial activity or expression of antigens typical for macrophages (Cousin et al. 1999 , Charriere et al. 2003 . Another important question is the possible phenotypic difference in the CD14 positive and the CD14 negative cell populations in the adipose tissue. In our study, bariatric surgery decreased the entire CD163 positive population as well as its CD14 positive subset, while only its CD14 negative fraction was elevated. These data suggest that, that the association of M2 macrophage phenotype with positive metabolic effects in humans may be more complex than anticipated by some previously published studies (Bourlier et al. 2008 , Zeyda et al. 2007 ). Our results also differ from a recently published immunochemistry study (Aron-Wisnewsky et al. 2009 ) where M2 macrophages increased after Roux-en-Y gastric bypass. Nevertheless, the disagreement between this and our study could be due to the usage of the CD206 marker for the identification of alternatively activated macrophages and from different methodologies used in these two studies.
In conclusion, we have demonstrated that obesity both with and without T2DM increases sCD163 levels without affecting CD163 mRNA expression in subcutaneous adipose tissue or CD14+ monocytes in blood. Furthermore, obesity increased the non-classical subset and decreased the classical subset of monocytes in blood. The decrease of classical monocytes was in relation with the reduction of CD163+CD14+ monocytes in peripheral blood. In subcutaneous adipose tissue of obese subjects, we identified two CD163 positive cell populations, which responded differently to body weight reduction after gastric plication. Taken together, increase of sCD163 levels could be useful for prediction of obesity and its metabolic complications while sCD163 or CD163 positive cells changes in peripheral blood or subcutaneous adipose tissue do not reflect precisely metabolic improvements after weight loss. 
